6-KThe Wire
NOVO NORDISK A S files 6-K
Filed May 22, 2026 · 1mo ago · Accession 0001171843-26-003645
Plain English
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Wegovy® 7.2 mg in a single-dose pen for obesity in the EU, with an expected launch in Q3 2026. In trials, this dosage demonstrated a mean weight loss of 20.7%.
Filing details
- Company
- NOVO NORDISK A S
- Ticker
- NVO
- CIK
- 353278
- Form type
- 6-K
- Filing date
- May 22, 2026
- Report date
- May 22, 2026
- Document
- f6k_052226.htm
- Size
- 166 KB